440 articles with MorphoSys AG
I-Mab Biopharma and MorphoSys Announce IND Clearance to Initiate Clinical Trials of TJ202/MOR202 for the Treatment of Multiple Myeloma in Mainland China
I-Mab Biopharma and MorphoSys AG announced that I-Mab has received Investigational New Drug clearances from the National Medical Products Administration of China to expand the ongoing phase II and III clinical trials of TJ202/MOR202, MorphoSys's human monoclonal anti-CD38 antibody for the treatment of multiple myeloma, also to mainland China.
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
MorphoSys AG will present at the following conferences
MorphoSys's Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya(R) (Guselkumab) for Treatment of Adults with Active Psoriatic Arthritis
MorphoSys AG announced that its licensee Janssen Research & Development, LLC issued a press release to report the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration seeking approval of Tremfya for the treatment of adult patients with active psoriatic arthritis.
MorphoSys Announces Intention to Submit Marketing Authorization Application for Tafasitamab to European Medicines Agency
MorphoSys AG announced its intention to submit a Marketing Authorization Application to the European Medicines Agency based on its phase 2 L-MIND study of tafasitamab and lenalidomide in relapsed or refractory diffuse large B cell lymphoma.
MorphoSys AG will publish its first six months' 2019 results on August 6, 2019 at 10:00pm CEST.
MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology
Vivoryon Therapeutics AG and MorphoSys AG today announced that they have entered into an agreement under the terms of which MorphoSys has obtained an exclusive option to license Vivoryon’s small molecule QPCTL inhibitors in the field of oncology.
MorphoSys's Licensing Partner GSK Initiates Phase 3 Clinical Program With Otilimab (MOR103/GSK3196165) in Rheumatoid Arthritis; MorphoSys Updates its Financial Guidance for 2019
MorphoSys AG announced that its licensing partner GSK reported in a press release earlier the start of a phase 3 clinical development program with otilimab in rheumatoid arthritis.
MorphoSys AG announced that its Supervisory Board has appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer.
MorphoSys Presents Primary Analysis Data from L-MIND Study of Tafasitamab (MOR208) in combination with Lenalidomide in r/r DLBCL at ICML 2019
MorphoSys AG presented data from the primary analysis of the ongoing single-arm phase 2 clinical trial known as L-MIND in an oral presentation at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland.
MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic Arthritis
MorphoSys AG announced that its licensee Janssen Research & Development, LLC, reported top-line results from the phase 3 DISCOVER 1 and 2 studies in a press release issued.
MorphoSys AG will present at the following conferences
All Resolutions Proposed by the Company's Management Approved
Ad hoc: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity
MorphoSys AG today announced results from the primary analysis (cut-off date November 30, 2018) of the ongoing single-arm phase 2 clinical trial known as L-MIND.
MorphoSys AG reports results for the first quarter of 2019.
The Management team of MorphoSys AG will host a conference call and webcast on May 8, 2019 at 2:00pm CEST (1:00pm BST; 8:00am EDT) to present MorphoSys's first quarter interim statement 2019 and provide an outlook for 2019.
MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple Myeloma
MorphoSys AG and I-Mab Biopharma announced that the first patient has been dosed in a phase 3 randomized and multi-center clinical study in Taiwan to evaluate MorphoSys's investigational human CD38 antibody MOR202/TJ202 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.
MorphoSys and Galapagos Announce Initiation of GECKO Phase 2 Study with MOR106 in Atopic Dermatitis Patients
MorphoSys AG, Galapagos NV and Novartis Pharma AG announced the initiation of GECKO, a phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.
Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
Galapagos NV, MorphoSys AG and Novartis Pharma AG announced the initiation of GECKO, a Phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.
MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Familial Adenomatous Polyposis
MorphoSys AG announced that its licensee Janssen Research & Development, LLC, has further expanded the clinical development of guselkumab) into familial adenomatous polyposis, a disease of the gastrointestinal tract.